Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$458.24 3.13 (0.68)%

High 461.94 Low 452.11 Volume 468,844 Market Cap 47.83B
05/24/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • May 24

    Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH

    Read on
  • May 22

    Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients

    Read on

EVENTS

  • Bernstein 33rd Annual Strategic Decisions Conference
    May 31, 2017 | 5:00 PM ET

  • 2017 Annual Meeting of Shareholders
    Jun 9, 2017 | 10:30 AM ET

Events & Presentations

NASDAQ REGN

$458.24 3.13 (0.68)%

High 461.94 Low 452.11 Volume 468,844 Market Cap 47.83B
05/24/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information